| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15524 R63789 |
Oberlander - Clonazepam (Controls unexposed, disease free), 2004 | Psychomotor developmental index from Bayley scales of infant development - At 8 months | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Co-administration extrapolated (cont. endpoint) Indication BZD: Psychiatric diseases (depression, anxiety, ...) |
2.18 [0.70;6.78] excluded (control group) |
-/18 -/23 | - | 18 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15525 R63795 |
Oberlander - Clonazepam (Controls unexposed, sick), 2004 | Psychomotor developmental index from Bayley scales of infant development - At 8 months | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Co-administration extrapolated (cont. endpoint) Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 0.73 [0.25;2.15] | -/18 -/28 | - | 18 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15570 R64093 |
Mortensen - BZDs, 2003 | Psychomotor development - Abnormal Boel test in one or more of the 14 items - Children aged 7–10 months | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes BZD Coexposure: Not specified | 7.70 [3.00;19.30] | 12/82 31/755 | 43 | 82 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15309 R62983 |
Laegreid b - BZDs, 1992 | Posture and motility - Touwen assessment - At 18 months of age | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) extrapolated (cont. endpoint) Indication BZD: Psychiatric diseases (depression, anxiety, ...) | 5.54 [1.68;18.28] | -/16 -/26 | - | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 3.17 [0.73;13.75] | 43 | 116 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 15524